Oceanpine Capital investee company——Chinese clinical-stage biotech firm TransThera Biosciences has raked in about $100mn in a series D round of financing from
China Merchants Capital and
6 other investors to futher the development of its pipeline in the global market.
Nanjing TransThera Biosciences Co., Ltd. is an innovative small molecule new drug R&D company in Jiangbei New Area, focusing on the development of innovative drugs that are not satisfied with clinical needs with obvious differentiation.
TransThera new drugs under research and development cover many diseases such as tumor and immunity. We will continue to innovate in the disease areas and strive to become a world-class biopharmaceutical company.
Source: Oceanpine Capital
